Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $206

Author: Benzinga Newsdesk | August 02, 2024 04:46pm
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $204 to $206.

Posted In: RMD

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist